Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide‐pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristicsPaul G. Richardson, Meletios Α. Dimopoulos, Larry D. Anderson et al.|European Journal Of Haematology|2021Cited by 11
Pomalidomide, bortezomib, and dexamethasone (PVd) in lenalidomide (LEN)-pretreated relapsed refractory multiple myeloma: Subanalysis of patients with renal impairment in OPTIMISMM.Fredrik Schjesvold, Paul G. Richardson, Meletios Α. Dimopoulos et al.|Journal of Clinical Oncology|2020Cited by 2